Acromegaly is curable in some cases. In patients who have a small pituitary gland tumor that can be removed via surgery, the ...

Crinetics plans to file for FDA approval if it gets positive results from a second, ongoing Phase 3 trial of the drug in acromegaly patients. The biotech expects results from that study ...

PATHFNDR-2 (NCT05192382) enrolled 111 adults with acromegaly who had elevated IGF-1 levels but were medication naïve or were not being treated with pharmacotherapy (untreated patients).

Paltusotine aims to provide a new once-daily oral treatment option for acromegaly patients, with regulatory reviews underway in both the U.S. and EU. Crinetics is also sponsoring a Product Theater ...

When an individualized approach was crafted based on predictive biomarker testing, 78% of patients with acromegaly achieved hormonal control compared with 53% of traditionally-treated patients ...

The investigational treatment suppresses growth hormone and insulin-like growth factor-1 (IGF-1) levels in acromegaly patients. The NDA is supported by data from 2 randomized, controlled phase 3 ...

Kshettry, with whom she usually sees patients, because she knew his expertise would also be needed. Yogi-Morren and Kshettry said Kohn had the clinical features of a disease called acromegaly ...

Mycapssa® is already approved in the United States for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with injectable octreotide or lanreotide.

PATHFNDR-2 (NCT05192382) enrolled 112 adults with acromegaly who had elevated IGF-1 levels but were medication naïve or were not being treated with pharmacotherapy (untreated patients).